Skip to main content
Sinocare Inc. logo

Sinocare Inc. — Investor Relations & Filings

Ticker · 300298 ISIN · CNE100001CJ0 LEI · 3003008DEKI00A51LU77 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,252 across all filing types
Latest filing 2017-06-30 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300298

About Sinocare Inc.

https://www.sinocare.com

Sinocare Inc. specializes in the research, development, and manufacturing of biosensor technology and rapid testing products for chronic disease management. The company is primarily recognized for its blood glucose monitoring systems, including meters and test strips, which serve a global patient base. Its product portfolio extends to point-of-care testing (POCT) solutions for HbA1c, uric acid, blood lipids, and other metabolic indicators. Through the integration of advanced sensing technologies and digital health platforms, Sinocare provides comprehensive diagnostic tools for diabetes and related metabolic disorders. The company focuses on delivering affordable and accurate monitoring solutions to improve the quality of life for individuals with chronic conditions worldwide.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于公司最近12个月内重大资产交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from CITIC Securities regarding major asset transactions of SanNuo Bio-sensing Co., Ltd. in the past 12 months. It details specific asset transactions and confirms that no major asset restructuring occurred under regulatory definitions. The document is a standalone audit or verification report related to asset transactions, not a full annual or interim report, nor an announcement or presentation. It fits the category of Audit Report / Information (AR) as it provides audit opinions on specific transactions without full financial statements or earnings data.
2017-06-30 Chinese
控股股东、实际控制人关于公司发行股票摊薄即期回报采取填补措施的承诺函
Regulatory Filings Classification · 95% confidence The document is a commitment letter from the controlling shareholders and actual controllers of the company regarding measures to compensate for the dilution of immediate returns caused by the company's stock issuance for asset purchase and fundraising. It references regulatory guidelines related to capital market investor protection and dilution of immediate returns. The document is a formal letter of commitment, not a financial report, audit, or announcement of voting results. It is a regulatory compliance document related to capital issuance but does not itself announce a capital change or financing update. Given its nature as a formal commitment letter, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2017-06-30 Chinese
全体董事、监事及高级管理人员关于所提供信息真实性、准确性和完整性的承诺函
Regulatory Filings Classification · 95% confidence The document is a formal commitment letter from all directors, supervisors, and senior management of SanNuo Bio-sensing Co., Ltd. regarding the truthfulness, accuracy, and completeness of information provided in relation to a major asset restructuring involving the acquisition of a 64.98% stake in Changsha SanNuo Health Management Co., Ltd. It references the "Reorganization Report (Draft)" and related disclosure documents but does not contain the report itself or detailed financial data. The document is a legal and compliance statement ensuring the integrity of information disclosed for the asset restructuring and the responsibilities of the parties involved. It is not a financial report, audit, or announcement of voting results but a regulatory compliance filing related to a major transaction. Given the nature and length (2171 characters), it is not a report publication announcement but a regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-06-30 Chinese
董事会关于本次重组符合《关于规范上市公司重大资产重组若干问题的规定》第四条规定的说明
Capital/Financing Update Classification · 95% confidence The document is a statement from the board of directors of 三诺生物传感股份有限公司 regarding a major asset restructuring involving the issuance of shares to purchase a significant equity stake in another company and related fundraising. It references compliance with regulatory provisions on major asset restructurings and details the transaction and its strategic rationale. The document is not a full financial report but an announcement explaining the compliance and rationale of a major asset restructuring transaction. It does not contain financial statements or detailed financial data. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes related to major transactions.
2017-06-30 Chinese
独立董事关于公司发行股份购买资产并募集配套资金事项的事前认可函
Capital/Financing Update Classification · 95% confidence The document is an independent director's pre-approval letter regarding the company's issuance of shares to purchase assets and raise supporting funds. It discusses the feasibility, compliance with laws and regulations, and fairness of the transaction and fundraising. The document is a formal opinion letter from independent directors, not a full report or announcement of financial results. It does not contain financial statements or detailed financial data but rather a regulatory compliance and approval statement related to a capital transaction. This fits best under Capital/Financing Update (CAP) as it relates to issuance of shares and fundraising activities.
2017-06-30 Chinese
第三届董事会第十次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting regarding a major asset restructuring involving issuance of shares to purchase assets and raise supporting funds. It includes specifics on transaction parties, asset valuation, share issuance details, lock-up periods, regulatory compliance, and references to Chinese securities laws and regulations. The document is lengthy (15,000 characters) and contains substantive content about the transaction, not just an announcement of a report or a brief summary. It is not a financial report like an annual or interim report, nor is it a call transcript or remuneration report. The content focuses on a capital raising and asset acquisition transaction, including issuance of shares and fundraising details. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2017-06-30 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.